Nasdaq · Healthcare

Esperion Therapeutics, Inc. (ESPR)

As-reported financials and recent SEC filings for Esperion Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$403.1M

Net income

$-22.7M

Net margin

-5.6%

Diluted EPS

$-0.11

ROE

7.5%

P/E (TTM)

—

Market cap

$816.9M

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$403.1M	$332.3M	$116.3M	$75.5M	$78.4M
Gross profit	—	—	—	—	—
Operating income	$60.3M	$54.4M	$-155.6M	$-179.5M	$-226.7M
Net income	$-22.7M	$-51.7M	$-209.2M	$-233.7M	$-269.1M
Diluted EPS	$-0.11	$-0.28	$-2.03	$-3.52	$-4.66

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-06-18

42026-06-18

42026-06-18

8-K/A2026-06-18

1442026-06-17

1442026-06-17

1442026-06-17

DEFA14A2026-06-16

Go deeper on ESPR

Search Esperion Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.